高聚金葡素治疗糖尿病的临床观察

Clinical Study on the Treatment Diabetes Mellitus withSuperantigenhighly Agglutinative Staphy Lococcin

采用超抗原生物制剂高聚金葡素的两种剂型（ＢＭ口服液和ＢＭ胶囊），分别协同治疗２０例糖尿病。结果：ＢＭ口服液组治后的血糖比治前下降３０．８９％，Ｐ＜０．００１；ＨｂＡ１Ｃ比治前下降３７．３３％，Ｐ＜０．００１。ＢＭ胶囊组治后的血糖比治前下降１３．７３％，Ｐ＜０．０５；ＨｂＡ１Ｃ比治前下降２９．３７％，Ｐ＜０．００１。胰岛素（３６例）治后增加５１．３％，Ｐ＜０．０１；４０例患者中Ｃ肽治后增加１９．３４％，Ｐ＜０．０５；４０例的Ｔ细胞亚群ＣＤ３治后增加１３．２％，Ｐ＜０．０１；ＣＤ４增加１７．４％，Ｐ＜０．００１；ＣＤ８减少１９．４％，Ｐ＜０．００１；ＣＤ４／ＣＤ８比值由１．０４转为１．５０，达到正常水平。表明高聚金葡素与降血糖药物合用对治疗糖尿病有明显的协同作用。其机理可能是通过超抗原的生物调节因子，调节机体内环境和细胞免疫功能所致。值得进一步深入研究。

The new biological response modifierhighly agglutinative staphy lococcin is the first superantigen biological agent in the world which has got various and obvious effect in clincal treatment.The cooperating treatment effect of its two productsBM oral liquids and BM capsule was observed in 20 diabetes cases.Blood glucose and HbA1C descended 30.89% BX(P<0.001) and 37.33% (P<0.001) separately in BM oral liquids group after treatment,compared with 13.73% (P<0.05) and 29.37%( P<0.001 ) in BM capsule group.Insulin and C petide were examined in 36 cases,which increased by 51.3%( P<0. 01 ) and 19.34% (P<0.05) separately after treatment.In 40 cases,CD3 and CD4 T cells were increased by 13.2% (P<0.01) and 17.4% (P<0.001), CD4/CD8 rose to 1.50 from 1.04 after treatment.It suggests that there is obvious synergic effect on diabetes with highly agglutinative staphy lococcin and glucoselowering drug.It may be resulted from the modification of inside circumstance and raise of the cell immunofunction by the biological factor of superantigen.The mechanism of which is worth further studying.